pyruvic acid has been researched along with Parkinson Disease in 16 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurodegenerative disorders have been considered as a growing health concern for decades." | 2.61 | Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration. ( Agrawal, N; Garabadu, D; Sharma, A; Sharma, S, 2019) |
| "Pyruvic acid is a neuronal metabolic energy fuel that can also rapidly undergo decarboxylation to diffuse H(2)0(2) into H(2)0." | 1.32 | Pyruvic acid cytoprotection against 1-methyl-4-phenylpyridinium, 6-hydroxydopamine and hydrogen peroxide toxicities in vitro. ( Mazzio, E; Soliman, KF, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Komilova, NR | 1 |
| Angelova, PR | 1 |
| Berezhnov, AV | 2 |
| Stelmashchuk, OA | 1 |
| Mirkhodjaev, UZ | 1 |
| Houlden, H | 1 |
| Gourine, AV | 1 |
| Esteras, N | 1 |
| Abramov, AY | 2 |
| Fedotova, EI | 1 |
| Dolgacheva, LP | 1 |
| Kim, YM | 1 |
| Choi, SY | 1 |
| Hwang, O | 1 |
| Lee, JY | 1 |
| Garabadu, D | 1 |
| Agrawal, N | 1 |
| Sharma, A | 1 |
| Sharma, S | 1 |
| Deus, CM | 1 |
| Pereira, SP | 1 |
| Cunha-Oliveira, T | 1 |
| Pereira, FB | 1 |
| Raimundo, N | 1 |
| Oliveira, PJ | 1 |
| Park, JS | 1 |
| Koentjoro, B | 1 |
| Davis, RL | 1 |
| Sue, CM | 1 |
| Ghosh, A | 1 |
| Tyson, T | 1 |
| George, S | 1 |
| Hildebrandt, EN | 1 |
| Steiner, JA | 1 |
| Madaj, Z | 1 |
| Schulz, E | 1 |
| Machiela, E | 1 |
| McDonald, WG | 1 |
| Escobar Galvis, ML | 1 |
| Kordower, JH | 1 |
| Van Raamsdonk, JM | 1 |
| Colca, JR | 1 |
| Brundin, P | 1 |
| Wallach, I | 1 |
| Jaitly, N | 1 |
| Lilien, R | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Mazzio, E | 1 |
| Soliman, KF | 1 |
| Winkler-Stuck, K | 1 |
| Wiedemann, FR | 1 |
| Wallesch, CW | 1 |
| Kunz, WS | 1 |
| Mytilineou, C | 1 |
| Werner, P | 1 |
| Molinari, S | 1 |
| Di Rocco, A | 1 |
| Cohen, G | 2 |
| Yahr, MD | 1 |
| Yamakawa, T | 1 |
| Ohta, S | 1 |
| Kesler, N | 1 |
| Nakagawa-Hattori, Y | 1 |
| Yoshino, H | 1 |
| Kondo, T | 1 |
| Mizuno, Y | 2 |
| Horai, S | 1 |
| Suzuki, K | 1 |
| Yoshida, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects on Physical Activity on Mitochondrial Function in Skin Fibroblasts in Patients With Parkinson's Disease: a Study Protocol.[NCT05963425] | 24 participants (Anticipated) | Interventional | 2023-09-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pyruvic acid and Parkinson Disease
| Article | Year |
|---|---|
Mitochondrial metabolism: a common link between neuroinflammation and neurodegeneration.
Topics: Alzheimer Disease; Animals; Citric Acid Cycle; Humans; Mitochondria; Neurodegenerative Diseases; Neu | 2019 |
15 other studies available for pyruvic acid and Parkinson Disease
| Article | Year |
|---|---|
Metabolically induced intracellular pH changes activate mitophagy, autophagy, and cell protection in familial forms of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Astrocytes; Autophagy; Cytoprotection; Dopaminergic Neurons; Fibroblasts; | 2022 |
Lactate and Pyruvate Activate Autophagy and Mitophagy that Protect Cells in Toxic Model of Parkinson's Disease.
Topics: Animals; Astrocytes; Autophagy; Cell Line, Tumor; Cell Survival; Humans; Lactic Acid; Membrane Poten | 2022 |
Pyruvate Prevents Dopaminergic Neurodegeneration and Motor Deficits in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Disease Models, Ani | 2022 |
Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson's disease patients uncovers metabolic and mitochondrial bioenergetic defects.
Topics: Aged; Energy Metabolism; Fibroblasts; Galactose; Glucose; Humans; Male; Metabolic Diseases; Middle A | 2020 |
Loss of ATP13A2 impairs glycolytic function in Kufor-Rakeb syndrome patient-derived cell models.
Topics: Cell Survival; Cells, Cultured; Glycolysis; Humans; Hydrogen Peroxide; Neurons; Parkinson Disease; P | 2016 |
Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Autophagy; Behavior, Animal; Brain; Caenorhab | 2016 |
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways.
Topics: Breast Neoplasms; Computational Biology; Databases, Factual; Diabetes Mellitus, Type 2; Drug-Related | 2010 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Pyruvic acid cytoprotection against 1-methyl-4-phenylpyridinium, 6-hydroxydopamine and hydrogen peroxide toxicities in vitro.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Hydrogen Peroxide; Hydroxydopamines; Neuroblastoma; Neuroprote | 2003 |
Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients.
Topics: Adenosine Diphosphate; Adult; Aged; Amobarbital; Antioxidants; Cells, Cultured; Coenzymes; Drug Inte | 2004 |
Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease.
Topics: Adult; Aged; Case-Control Studies; Cells, Cultured; Decarboxylation; Evaluation Studies as Topic; Fe | 1994 |
Isolation of 1-methyl-1,2,3,4-tetrahydroisoquinoline-synthesizing enzyme from rat brain: a possible Parkinson's disease-preventing enzyme.
Topics: Animals; Brain; Chromatography, Gel; Deoxycholic Acid; Hydrogen-Ion Concentration; Isoquinolines; Ma | 1997 |
Monoamine oxidase and mitochondrial respiration.
Topics: Animals; Disulfides; Electron Transport; Electron Transport Complex I; Glutathione; Hydrogen Peroxid | 1999 |
Is Parkinson's disease a mitochondrial disorder?
Topics: Aerobiosis; Aged; Blotting, Southern; DNA, Mitochondrial; Exercise Test; Humans; Lactates; Lactic Ac | 1992 |
Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain.
Topics: Adenosine Triphosphate; Animals; Brain; Glutamates; Glutamic Acid; Humans; Isoquinolines; Malates; M | 1990 |